NASDAQ:ADIL - Adial Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.70 -0.40 (-5.63 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$6.70
Today's Range$6.31 - $8.00
52-Week Range$1.11 - $9.44
Volume551,700 shs
Average Volume1.33 million shs
Market Capitalization$46.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADIL
CUSIPN/A
Phone434-422-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees3
Market Cap$46.55 million
OptionableNot Optionable

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced its earnings results on Wednesday, November, 14th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.54. View Adial Pharmaceuticals' Earnings History.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Adial Pharmaceuticals.

What price target have analysts set for ADIL?

2 brokerages have issued 1 year price objectives for Adial Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 25.4%. View Analyst Price Targets for Adial Pharmaceuticals.

What is the consensus analysts' recommendation for Adial Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.

Has Adial Pharmaceuticals been receiving favorable news coverage?

News coverage about ADIL stock has been trending extremely positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a news sentiment score of 4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the next several days.

Who are some of Adial Pharmaceuticals' key competitors?

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the folowing people:
  • Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
  • Mr. Joseph M. Truluck MBA, CFO & COO (Age 41)
  • Dr. Tomasz H. Zastawny Ph.D., DSc, Chief Devel. Officer
  • Ms. Monika Z. Rogozinska, Sr. VP of Drug & Bus. Devel.
  • Mr. Lawrence Goldman, Controller (Age 63)

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

When does the company's lock-up period expire?

Adial Pharmaceuticals' lock-up period expires on Wednesday, January 23rd. Adial Pharmaceuticals had issued 1,464,000 shares in its public offering on July 27th. The total size of the offering was $7,320,000 based on an initial share price of $5.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $6.70.

How big of a company is Adial Pharmaceuticals?

Adial Pharmaceuticals has a market capitalization of $46.55 million. Adial Pharmaceuticals employs 3 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is http://www.adialpharma.com.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 SEMINOLE TRAIL SUITE 495, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-422-9800 or via email at dwaldman[email protected]


MarketBeat Community Rating for Adial Pharmaceuticals (NASDAQ ADIL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel